AMLX - Amylyx down 6% despite encouraging phase 2 data on rare disorder drug
2024-04-10 11:04:01 ET
More on Amylyx Pharmaceuticals
- An ALS Drug Fails Again
- Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
- Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2023 Earnings Call Transcript
- Amylyx pulls ALS therapy Relyvrio from the market
- Mizuho downgrades Amylyx to Neutral after ALS trial setback